Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines

Journal of Applied Toxicology

Volumn 35, Issue 12, 2015, Pages 1564-1576

  Segal, Lawrence ^a   Wouters, Sandrine ^a   Morelle, Danielle ^a   Gautier, Gaëlle ^b   Le Gal, Julien ^b   Martin, Thomas ^c   Kuper, Frieke ^d   Destexhe, Eric ^a   Didierlaurent, Arnaud M ^a   Garçon, Nathalie ^a,e  

^a GSK   (Belgium)

^b CHELATEC   (France)

^c Department of Environmental Air Quality   (United Kingdom)

^d TNO   (Netherlands)

^e BIOASTER   (France)

Author keywords

Adjuvant system; Inflammation; Influenza; Pandemic; Split influenza antigen; Vaccine

Indexed keywords

ALBUMIN; FIBRINOGEN; GLOBULIN; INFLUENZA VACCINE; VIRUS ANTIGEN; ALPHA TOCOPHEROL; ASO3B ADJUVANT; CARBON; DRUG COMBINATION; POLYSORBATE; SQUALENE; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; INFLAMMATION; INFLUENZA A VIRUS (H5N1); INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; ISOTOPE LABELING; LYMPH NODE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; OPHTHALMOSCOPY; ORGAN WEIGHT; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RECTUM TEMPERATURE; REPEATED DRUG DOSE; ANIMAL; C57BL MOUSE; DISEASE OUTBREAKS; DRUG COMBINATION; HUMAN; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; PRECLINICAL STUDY; RABBIT; TISSUE DISTRIBUTION;

ALPHA-TOCOPHEROL; ANIMALS; CARBON RADIOISOTOPES; DISEASE OUTBREAKS; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; RABBITS; SQUALENE; TISSUE DISTRIBUTION; TRITIUM;

EID: 84945489823     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3130     Document Type: Article

References (35)

1. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3: e1401.
2. Brigelius-Flohé R, Traber MG. 1999. Vitamin E: function and metabolism. FASEB J. 13: 1145-1155.
3. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A. 2013. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31: 3363-3369.
4. A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 27: 7428-7435.
5. Cray C, Zaias J, Altman NH. 2009. Acute phase response in animals: a review. Comp. Med. 59: 517-526.
6. Destexhe E, Prinsen MK, van Scholl I, Kuper CF, Garçon N, Veenstra S, Segal L. 2013. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. J. Pharmacol. Toxicol. Methods DOI: 10.1016/j.vascn.2013.04.003.
7. Dimitriou ID, Clemenza L, Scotter AJ, Chen G, Guerra FM, Rottapel R. 2008. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol. Rev. 224: 265-283.
8. Do R, Kiss RS, Gaudet D, Engert JC. 2009. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin. Genet. 75: 19-29.
9. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del GG, Rappuoli R. 2011. Influenza vaccine immunology. Immunol. Rev. 239: 167-177.
10. Draize JH, Woodard G, Calvery HO. 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Therap. 82: 377-390.
11. EMA-CPMP. 1997. Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004004.pdf [10 May 2013].
12. European Commission. 1986. Directive 86/69/EEC on the protection of animals used for scientific purposes. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1986:358:0001:0028:EN:PDF [6 August 2013].
13. FDA-CBER. 2006. Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092170.pdf [10 May 2013].
14. Fox CB, Haensler J. 2013. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev. Vaccines 12: 747-758.
15. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
16. Garçon N, Vaughn DW, Didierlaurent AM. 2012. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11: 349-366.
17. Hessel L. 2009. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Influenza Other Respi. Viruses 3: 165-170.
18. Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC. 2012. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J. Infect. Dis. 206: 811-820.
19. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3: 85ra48.
20. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J. Infect. Dis. 201: 1644-1653.
21. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. 2011. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J. Infect. Dis. 203: 1729-1738.
22. Leroux-Roels G. 2009. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin. Biol. Ther. 9: 1057-1071.
23. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster J M, Leroux-Roels G. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
24. A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28: 849-857.
25. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios G M, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El I M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L. 2013. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. 13: 485-496.
26. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garcon N, Van Mechelen M. 2011. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29: 2461-2473.
27. Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB, Zambrana-Torrelio C, Lipkin WI, Daszak P. 2012. Prediction and prevention of the next pandemic zoonosis. Lancet 380: 1956-1965.
28. National Toxicology Program. 1992. NTP Toxicology and Carcinogenesis Studies of Polysorbate 80 (CAS No. 9005-65-6) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl. Toxicol. Program Tech. Rep. Ser. 415: 1-225.
29. A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28: 1740-1745.
30. Rümke HC, Bayas J M, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santos F, von Sonnenburg F, Dramé M, Sänger R, Ballou WR. 2008. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26: 2378-2388.
31. Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M. 2012. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum. Vaccin. Immunother. 8: 1283-1292.
32. Webster RG, Govorkova EA. 2006. H5N1 influenza--continuing evolution and spread. N. Engl. J. Med. 355: 2174-2177.
33. WHO. 2003. WHO guidlines on nonclinical evaluation of vaccines. http://www.who.int/biologicals/publications/nonclinical_evaluation_vaccines_nov_2003.pdf [10 May 2013].
34. WHO. 2013a. Pandemic Influenza Risk Management: WHO Interim Guidance. http://www.who.int/influenza/preparedness/pandemic/influenza_risk_management/en/index.html [5 August 2013].
35. WHO. 2013b. WHO guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. http://www.who.int/biologicals/areas/vaccines/ADJUVANTS_Post_ECBS_edited_clean_Guidelines_NCE_Adjuvant_Final_17122013_WEB.pdf [4 June 2014].